NAFLD/NASH in patients with type 2 diabetes and related treatment options.

about

Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats

P2860

Q58739563-2B688D37-83AE-4E83-9418-D4E21E5F51D1 Q58773071-C7E7E8B0-8994-49A9-B51F-5867227111F6

P2860

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Item

http://www.wikidata.org/entity/Q47592767

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

@en

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

@nl

type

Item

label

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

@en

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

@nl

prefLabel

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

@en

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

@nl

P1476

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

@en

P2093

F Martucci

http://www.w3.org/2001/XMLSchema#string

G Castoldi

http://www.w3.org/2001/XMLSchema#string

G Lattuada

http://www.w3.org/2001/XMLSchema#string

G Manzoni

http://www.w3.org/2001/XMLSchema#string

M G Radaelli

http://www.w3.org/2001/XMLSchema#string

S Accornero

http://www.w3.org/2001/XMLSchema#string

S Perra

http://www.w3.org/2001/XMLSchema#string

P2860

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome

Steatohepatitis: a tale of two "hits"?

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study (Data from an Epidemiological Study on the Insulin Resistance syndrome).

P2888

s40618-017-0799-3

P304

509-521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S40618-017-0799-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gianluca Perseghin

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29189999

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

about

P2860

P2860

NAFLD/NASH in patients with type 2 diabetes and related treatment options.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921